Latest Industrial Scale Up News

Mesoblast Limited is set to release its full-year financial results and operational highlights for 2025, spotlighting its FDA-approved cell therapy and expanding global partnerships.

Octava Minerals reports impressive initial bioleaching recoveries of critical rare earth elements and lithium from its Byro Project, highlighting a promising, low-cost extraction pathway.

AML3D has appointed Arc Additive as its UK and European distribution partner, marking a strategic push into key manufacturing and defence markets across Europe. This move follows a successful capital raise and a contract with BAE Systems UK, underpinning AML3D’s growth ambitions.

Titomic Limited has successfully raised A$50 million through a strategic share placement, aiming to fuel its growth in industrial-scale metal additive manufacturing. The capital raise underscores investor confidence as the company prepares to expand its global footprint.

Vulcan Energy has won up to €104 million in grants from German federal and state governments to advance its sustainable lithium production project, bolstering Europe’s electric vehicle battery supply chain.

Hazer Group has forged a strategic alliance with engineering giant KBR to fast-track commercial deployment of its methane pyrolysis technology, supported by a $10.7 million capital raise and promising project developments in Japan.

Mesoblast has secured FDA agreement on key requirements for its Biologics License Application for Revascor, targeting ischemic heart failure patients with reduced ejection fraction. The company aims for accelerated approval by year-end 2025.

Proteomics International, alongside key partners, is investing $6 million to expand the WA Proteomics Facility, aiming to establish a nationally accredited platform for industrial-scale protein biomarker analysis in medicine and agriculture.

MTM Critical Metals has raised A$50 million through a well-supported institutional placement to accelerate the rollout of its proprietary Flash Joule Heating technology in the U.S. This capital injection marks a pivotal step in MTM’s transformation into a U.S.-focused clean technology company.

Mesoblast reports positive FDA progress on accelerated approval for Revascor in ischemic heart failure and plans a pivotal trial to extend Ryoncil’s label to adults with graft versus host disease, while its US commercial launch outpaces expectations.

Provaris Energy has partnered with Yinson to develop large-scale liquid CO2 storage tanks and shipping solutions, aiming to meet surging demand in the expanding carbon capture and storage market.

Hazer Group has entered a binding six-year strategic alliance with global engineering leader KBR to exclusively market and license its methane pyrolysis technology, targeting the ammonia and methanol sectors. This partnership aims to accelerate commercialisation, expand global reach, and materially de-risk Hazer’s business plan.